Can Cholesterol Lowering Drugs Influence Circulating Omega-3 Fatty Acid Levels

• Status: Completed
• Trial end date: 2015-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The objective of this study is to determine if the administration of a cholesterol lowering drug like ezetimibe will reduce circulating omega-3 fatty acid (ALA) levels in patients with heart disease and hypercholesterolemia.

The investigators hypothesize that their data will discover that patients receiving ezetimibe require additional dietary supplementation with omega-3 supplements to insure that these beneficial fatty acids are available to these patients.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Manitoba
• Collaborator: Canadian Institutes of Health Research (CIHR)
• Treatments: Anticholesteremic Agents; Ezetimibe

Criteria

Inclusion Criteria:

• The subject is between 18-80 years old

• The subject lives in Winnipeg area

• The subject is willing to seize intake of oils/ salad dressings/ seafood

• The subject is willing to comply with the study schedule

Exclusion Criteria:

• The subject had been taking flax oil in the last month

• The subject is not willing to undergo dietary restrictions